Last Updated: 06 Nov 2024
Executive Summary
Illumina Inc. (ILMN) is a leading provider of genetic sequencing and analysis systems. The company's products and services are used in a wide range of applications, including medical research, clinical diagnostics, and agricultural biotechnology. Illumina has a strong track record of innovation and growth, and is well-positioned to benefit from the continued growth of the genetic sequencing market.
Company Overview
Illumina was founded in 1998 and is headquartered in San Diego, California. The company has a global presence, with operations in over 100 countries. Illumina's products and services are used by a wide range of customers, including academic institutions, hospitals, clinical laboratories, and biotechnology companies.
Fundamental Analysis
Illumina's financial performance has been strong in recent years. The company's revenue has grown at a compound annual growth rate (CAGR) of 15% over the past five years. Illumina's profitability has also improved in recent years, with the company's operating margin increasing from 15% in 2017 to 23% in 2022.
Illumina's balance sheet is also strong. The company has a low level of debt and a large amount of cash on hand. This gives Illumina the financial flexibility to invest in new products and services, and to make acquisitions.
Technical Analysis
Illumina's stock price has been trending higher in recent years. The stock price has more than doubled since the beginning of 2020. Illumina's stock price is currently trading above its 50-day and 200-day moving averages. This indicates that the stock is in a bullish trend.
Short Term Outlook
Illumina's short-term outlook is positive. The company is expected to continue to benefit from the growth of the genetic sequencing market. Illumina is also expected to benefit from the launch of new products and services.
Long Term Outlook
Illumina's long-term outlook is also positive. The genetic sequencing market is expected to continue to grow in the coming years. Illumina is well-positioned to benefit from this growth, given its strong track record of innovation and its large installed base of customers.
Analyst Recommendations
The majority of analysts have a positive outlook on Illumina. The average analyst target price for Illumina is $157.5, which is above the current stock price. Eight analysts have a "Strong Buy" rating on Illumina, five have a "Buy" rating, and 11 have a "Hold" rating. Only one analyst has a "Sell" rating on Illumina.
